Stockwinners Market Radar for January 25, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:26 EST Cathie Wood's ARK Investment bought 711K shares of Ginkgo Bioworks today

18:48 EST ResMed CEO: Our resupply rate is higher due to GLP-1 drugs - In an interview on CNBC's Mad Money, Mick Farrell said ResMed only has about 15%-20% market penetration in the U.S. for sleep apnea products, so there is plenty of runway ahead.

18:07 EST Disc Medicine director sells $6.93M in common stock - In a regulatory filing, Disc Medicine disclosed that its director Kevin Bitterman sold 102.5K shares of common stock on January 23rd in a total transaction size of $6.93M.

17:26 EST Hyzon Motors delivers four FCEVs to Performance Food Group - Hyzon Motors (HYZN) announced that it delivered four FCEVs to leading food distributor and supplier Performance Food Group (PFGC), in a joint ceremony. The event, held at PFG's Vistar facility in Fontana, was attended by local government officials, company leaders, and PFG associates, and showcased the new FCEVs by offering ride along demonstrations.

17:21 EST Western Digital says 30% gross margin within reach - The company states: "When you look at what we delivered in the second quarter and when you also look at the guide, it does reflect continuous margin improvement on the HDD side. And so I also anticipate that there should be continuous improvement as the recovery continues in that business. So 30% is very much within reach, and we should be able to achieve it pretty soon. On the flash side, the -- a lot has to do with continuing to optimize the product mix to drive that ASP up. and also, of course, continuing to deliver on our cost reduction. And so on the cost reduction we've done well so far. We've been in the mid-teens. I expect us to also hit that mid-teens percentage cost reduction for this fiscal year -- so as the pricing continues to improve, I would anticipate that we would be -- we would also be there in the -- let's say, in the next few quarters." Comments taken from Q2 earnings conference call.

17:02 EST Northern Star Investment Corp. II to liquidate trust account - Northern Star Investment Corp. II "announced that, because it will not be able to consummate an initial business combination as described in the Company's amended and restated certificate of incorporation by the current January 28, 2024 deadline, it has determined to commence the process of liquidating the trust account established in connection with the Company's initial public offering and distributing funds to holders of the Company's shares of Class A Common Stock sold in the IPO. Additionally, as the Company has not consummated an initial business combination by the January 28, 2024 deadline, the Company expects the NYSE American to take delisting action with regard to the Company's securities. The Company has further determined to continue its corporate existence following the distribution of funds in the trust account in an effort to acquire a business or entity."

16:56 EST KLA Corp. down 6% at $604.18 after Q2 results, below-consensus guidance

16:53 EST Orsted, Eversource propose updated sunrise wind project for New York - Joint venture partners Orsted and Eversource "submitted a new proposal for Sunrise Wind in response to New York's latest offshore wind solicitation, re-bidding an updated project that, if selected, would fulfill its promise to deliver substantial economic benefits across New York and play a critical role in advancing the state's climate goals. Sunrise Wind would deliver up to 924 megawatts of clean energy to New York. As the most mature offshore wind project in the state's pipeline, Sunrise Wind is expected to be completed in 2026, helping the state achieve its mandate of 70% renewable energy by 2030, while paving the way for future state projects and accelerating the state's growing offshore wind workforce and supply chain."

16:37 EST Titan Pharmaceuticals fully compliant with NASDAQ listing criteria - Titan Pharmaceuticals announced that by letter dated January 2 the Company was notified by The Nasdaq Stock Market that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter has been closed.

16:34 EST Empire State Realty signs new full-floor lease with GNY Mutual - Empire State Realty Trust announced that it signed Greater New York Mutual Insurance Company for a new full-floor, 52,116 square foot space at the world-famous Empire State Building. GNY Mutual has served policyholders since 1914 and earned an A+ (Superior) rating from A.M. Best for more than 30 consecutive years. "As a 109-year-old insurance company who specializes in providing coverage solutions for commercial real estate owners, we appreciate the significance of the Empire State Building to the NYC real estate community," said Elizabeth Heck, chairman, president, and CEO of GNY Mutual. "As an employer, we are attracted to ESB for its industry-leading sustainability measures and excellent tenant amenities which aid in employee recruitment and retention in addition to our hybrid work environment."

16:31 EST SOC sends letter to Starbucks holders calling for new approach to labor issues - The Strategic Organizing Center, a shareholder of Starbucks, sent a letter to its fellow shareholders outlining why enhanced oversight and proven human capital management expertise is needed on Starbucks' Board of Directors. "As a shareholder of Starbucks and as an ally to Starbucks employees - many of whom are also shareholders through the Company's share ownership program - the Strategic Organizing Center (the "SOC") is seeking to bring urgently needed change to Starbucks' boardroom," the company said. "We believe the current Board has tolerated an unacceptable level of reputational risk, a counterproductive approach to labor issues and a flawed allocation of resources. For these reasons - and to protect shareholder value - we have nominated three director candidates (the "SOC Nominees"), who are ideally suited to help repair the relationship with the Company's workers and regulators while safeguarding the best interests of all Starbucks' stakeholders. You can support this change and be part of ensuring Starbucks returns to the right path for the future. We urge you to use the enclosed BLUE proxy card to vote "FOR" each of the SOC Nominees today. You can also vote for the SOC Nominees on the Company's White proxy card. We strongly believe that voting for the SOC Nominees will help ensure the status quo does not continue, and that shareholder value does not suffer in the same way the Company's reputation has."

16:27 EST KLA Corp. sees Q3 adjusted gross margin 61.5% +/- 1.0% - Q3 GAAP gross margin is expected to be in a range of 59.4% +/- 1.0%.

16:23 EST Acuity Brands increases quarterly dividend 15% to 15c per share - Acuity announced that its board of directors increased its quarterly dividend by 15% to 15c per share from 13c per share. The dividend is payable on February 14 to shareholders of record on February 5. In addition, the board authorized the additional repurchase of up to 3M shares of common stock, bringing the outstanding authorization to approximately 3.9M shares.

16:17 EST Energy Transfer LP raises quarterly distribution 3.3% to 31.5c per share - Energy Transfer LP announced an increase in its quarterly cash distribution to 31.5c per Energy Transfer common unit for the fourth quarter ended December 31, 2023. This cash distribution per Energy Transfer common unit will be paid on February 20, 2024 to unitholders of record as of the close of business on February 7, 2024, and is an increase of 3.3% as compared to the fourth quarter of 2022.

16:14 EST Capital One reports Q4 net interest margin of 6.73%, up 4 bps vs. Q3 - Reports Q4: Provision for credit losses increased $573 million to $2.9 billion: Net charge-offs of $2.5 billion. $326 million loan reserve build. All metrics vs. Q3.

16:10 EST Grocery Outlet names Ramesh Chikkala to EVP COO, effective January 22 - Grocery Outlet Holding announced that it has appointed Ramesh Chikkala to the newly created position of EVP, Chief Operations Officer, effective January 22 . This strategic appointment marks a significant milestone as Grocery Outlet continues to scale its business and add additional supply chain and business technology experience to its organization. In this newly created COO position, Mr. Chikkala will lead the Company's Supply Chain and Business Technology functions, reporting to RJ Sheedy, President and Chief Executive Officer.

16:09 EST Visa sees Prosa deal closing during 2H24

16:08 EST Visa CEO: 2024 off to a solid start - CEO Ryan McInerney commented: "Our 2024 fiscal year is off to a solid start. In our first quarter, net revenues grew 9% and GAAP EPS grew 20%, driven by relatively stable growth in overall payments volume and processed transactions, plus strong growth in cross-border volume. Consumer spending remained resilient. Looking ahead, we continue to see significant opportunity across consumer payments, new flows and value added services."

16:08 EST Porch Group gets $25M with strategic agreement with Aon - Porch Group "announced it signed a strategic business collaboration agreement with Aon Corp. and Aon Re, Inc. to provide a variety of services to Porch Group companies, resulting in payments to Porch of approximately $25 million upfront and an expected approximately $5 million over the following four years. Aon Re, Inc. is a leading reinsurance broker and provides a wide variety of services for insurance and non-insurance companies. Reinsurance brokers are specialists who arrange reinsurance coverage for insurance companies. Porch was seeking a strong partner who could both deliver strong outcomes with reinsurance placements and importantly, provide other services across Porch Group such as data modeling and more. Aon and Porch Group will work together to place 2024 reinsurance coverage at the upcoming renewal on April 1, 2024."

16:04 EST Archrock increases quarterly cash dividend 6.5% to 16.5c per share - Archrock announced that its board of directors has declared an increased quarterly dividend of 16.5c per share of common stock, or 66c per share on an annualized basis. The fourth quarter 2023 dividend will be paid on February 13 to all stockholders of record on February 6. The fourth quarter 2023 dividend per share amount represents an increase of 6.5% over the Archrock third quarter 2023 dividend level and an increase of 10% over the Archrock fourth quarter 2022 dividend level.

16:04 EST T-Mobile down 3% at $157.49 afterhours following Q4 results and guidance

16:02 EST Freedom Holding announces completion of external review into short report - Freedom Holding Corp. announced the conclusion of an external review commissioned by the independent members of its board of directors. The external review was into wide-ranging allegations made about the Company and its business in an August 15, 2023 report published by Hindenburg Research, an activist short-selling firm which disclosed having a short position in the Company's shares. Following the publication of the Hindenburg Report, although the Company believed the allegations were meritless and the independent directors have full confidence in the Company and its business model, the independent members of the Company's board of directors decided that it was in the best interests of the Company and its shareholders to conduct an external review of the allegations set out in the Hindenburg Report. The external review found generally that the allegations in the Hindenburg Report did not take account of important facts and were not supported by evidence. In particular, the findings of the external review included the following: The Company's growth in recent years was mainly attributable to organic growth (including increases in the number of customers and increased trading volume by customers), acquisitions and gains and income from trading securities, as described in the Company's reports filed with the SEC and as indicated in its audited financial statements. The growth was not the result of manipulative or otherwise illegal or improper business practices. The Company has robust global and local sanctions and anti-money laundering ("AML") procedures, controls and policies in place, which are implemented through its business and compliance personnel. There was no evidence identified of sanctions evasion or dealing with sanctioned oligarchs. While certain of the Company's non-US subsidiaries have had dealings with certain sanctioned banks and individuals, a fact which the Company has publicly disclosed, those dealings did not involve any material violations of US, EU, UK, or other sanctions. There was no evidence identified of client accounts being funded with cryptocurrencies or physical cash, other than cash deposits made by existing customers at the Bank Freedom Finance Kazakhstan JSC retail banking counter subject to standard AML checks. There was no evidence identified that the Company has engaged in market manipulation of its own stock or in respect of its holdings of Kazakhstan Sustainability Fund bonds. The Company's holdings of fixed coupon Kazakhstan Sustainability Fund bonds do currently have a negative carry, as is alleged, but are held as part of a deliberate and legitimate trading strategy which is anticipated to be profitable as a result of future interest rate movements. The Company maintains policies, procedures and controls for the business dealings between its Cyprus subsidiary, Freedom Finance Europe Limited, and FST Belize, including with regard to anti-money laundering compliance and sanctions compliance. There was no evidence identified to support the allegations made in the Hindenburg Report that the Company engaged in transactions with FST Belize in order to generate "fake" or inflated revenue. The Company's former Russian subsidiaries were sold in a valid sale transaction and there is no evidence to support continuing control by the Company or the Company's CEO Timur Turlov of the Russian companies following that sale. The Company's brokerage clients were not required to purchase the Company's stock in order to receive allocations of shares in US IPOs or to participate in a program to acquire shares from US IPOs in the secondary market at or near the IPO share price. The Company has accepted the results of the external review and, in particular, welcomes the finding that it has robust global and local sanctions and AML procedures, controls and policies in place. As part of its commitment to strong governance and compliance the Company asked the external review team to recommend any enhancements that could be made to such procedures, controls and policies based on their review. In response, and in conjunction with delivering its findings, the external review team has recommended certain further enhancements, and the Company's board of directors has accepted those recommendations. Senior management of the Company, including the Vice President of Compliance, have already begun to implement them."

16:00 EST Jin Medical International Ltd trading resumes

15:49 EST Jin Medical International Ltd trading halted, volatility trading pause

15:18 EST BP to take ownership of Equinor's 50% stake in Beacon Wind US offshore projects - BP (BP) and Equinor (EQNR) announced an agreement to restructure the ownership of their joint U.S. offshore wind projects which, following completion, will result in BP taking ownership of Equinor's 50% stake in the Beacon Wind 1 and 2 projects and Equinor taking ownership of BP's 50% stake in the Empire Wind 1 and 2 projects. In addition, BP agrees to take ownership of Equinor's 50% interest in the Astoria Gateway for Renewable Energy site and, subject to certain future conditions, Equinor agrees to take ownership of bp's 50% interest in the South Brooklyn Marine Terminal. BP will take ownership of Equinor's 50% stake in the Beacon Wind US offshore wind projects, located in federal waters between Cape Cod, Massachusetts, and Long Island, New York. Beacon Wind 1 and 2 have the combined potential to deliver renewable energy to over 2 million consumers in the northeastern U.S. Meanwhile, Equinor will take ownership of BP's 50% stake in the Empire Wind US offshore wind projects, located 15-30 miles southeast of Long Island. Previously, BP and Equinor each held a 50% stake in the Beacon and Empire offshore wind projects. Under the new agreement, the companies will work independently to develop their wholly owned projects. The pair have also agreed with the New York State Energy Research and Development Authority, or NYSERDA, to terminate the Offshore Wind Renewable Energy Certificate Purchase and Sale Agreement for the Beacon Wind 1 project. "The agreement aims to help each company optimize their development strategies, strengthen their positions in the US offshore wind market and continue supporting the energy transition," BP stated. Reference Link

15:11 EST Gol Linhas, subsidiaries initiated voluntary U.S. bankruptcy reorganization - In a regulatory filing, GOL Linhas Aereas Inteligentes S.A. disclosed that the company announced that GOL and its subsidiaries have initiated voluntary reorganization proceedings under Chapter 11 of the United States Bankruptcy Code, or "Chapter 11," in the United States Bankruptcy Court for the Southern District of New York and issued a press release in connection therewith. "GOL and its filing subsidiaries and affiliates intend to continue to operate their businesses as 'debtors in possession' under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code during the pendency of the Chapter 11 process," the company stated. "GOL enters the U.S. legal process with a financing commitment for US$950 million in new debtor-in-possession financing from members of the Ad Hoc Group of Abra Bondholders, as well as certain other Abra bondholders. The Company will seek access to this funding as part of its First Day hearing in the coming days. The financing is subject to court approval and, along with cash generated from ongoing operations, will provide substantial liquidity to support operations in the normal course during the Chapter 11 process. With the support of the court-supervised process and the additional liquidity from the DIP financing, GOL's passenger flights, its GOLLOG cargo flights, Smiles Loyalty program and other company operations are continuing in the normal course. The Company will continue providing safe and reliable air travel service at a low cost, providing the best travel experience to its customers. Customers will be able to continue to arrange travel and fly in the same manner they always have, including the use of tickets and vouchers, and the accrual, purchase and use of miles earned through Smiles. GOL's codeshare and interline agreements will also continue to be available to customers," the company added.

14:48 EST GOL Linhas trading halted, news pending

13:09 EST Vanda announces publication of journal article on Tradipitant study - Vanda Pharmaceuticals announced the publication of an article titled "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology Journal, which follows a previously published study of tradipitant in the treatment of gastroparesis in 2021. "The findings of this pivotal phase III study are included in the New Drug Application for tradipitant in the treatment of gastroparesis in adults submitted to the U.S. Food and Drug Administration. The FDA has set a Prescription Drug User Fee Act target action date of September 18, 2024 for its decision," the company stated.

13:03 EST Apple announces new business terms for developers' apps in EU - Also today, Apple is sharing new business terms available for developers' apps in the European Union. Developers can choose to adopt these new business terms, or stay on Apple's existing terms. Developers must adopt the new business terms for EU apps to use the new capabilities for alternative distribution or alternative payment processing. Developers operating under either set of business terms can continue to use the App Store's secure payment processing and share their apps on the App Store in the EU. And both sets of business terms reflect Apple's long-standing work to make the app ecosystem the best opportunity for all developers. The new business terms for apps in the EU are necessary to support the DMA's requirements for alternative distribution and payment processing. That includes a fee structure that reflects the many ways Apple creates value for developers' businesses - including distribution and discovery on the App Store, the App Store's secure payment processing, Apple's trusted and secure mobile platform, and all the tools and technology to build and share innovative apps with users around the world. Developers operating under the new business terms will have the option to distribute their iOS apps from the App Store and/or alternative app marketplaces. These developers can also choose to use alternative payment processors in their EU apps on the App Store, across Apple's operating systems. The new business terms for iOS apps in the EU have three elements: reduced commission, payment processing fee, and core technology fee.

12:51 EST PayPal lower as company announces six new AI innovations - Shares of PayPal are down $2.98, or nearly 5%, to $60.04 in afternoon trading as the company announced six new innovations the company is piloting and bringing to market this year to "revolutionize commerce through artificial intelligence driven personalization for both merchants and consumers." The company stated: "During the PayPal First Look keynote, Alex Chriss, President and CEO, introduced: a completely new PayPal checkout experience that radically speeds up check out for consumers and helps merchants convert transactions like never before; Fastlane by PayPal, a dramatically faster and smarter guest checkout experience; Smart Receipts, giving customers AI-personalized recommendations from merchants to keep them coming back; the PayPal advanced offers platform so merchants can provide relevant, personalized, real-time offers to consumers and drive more sales; a reinvented PayPal consumer app giving shoppers new ways to earn cash back and more reasons to use PayPal; and, Venmo's enhanced business profiles, so small businesses can find and engage new customers, and grow their businesses." President and CEO Alex Chriss added: "With nearly 400 million consumer accounts, and 35 million merchant accounts, PayPal handles transactions for about a quarter of the world's e-commerce transactions each year, but more importantly, shoppers trust PayPal to power their payments. PayPal is introducing six new innovations that will not only solve real customer pain points, but we believe will change the world of payments and commerce. From new solutions for merchants to speed up checkout and personalize offers, to a new consumer app that will give our loyal customers more reasons to shop with PayPal, to the next generation of Venmo designed to be the growth platform for local small businesses, PayPal has always brought the future of money to our consumers and merchants and today marks the next revolution."

12:48 EST Southwest says balance sheet strength continues to be financial backbone

12:42 EST PayPal down 4% as company hosts innovations preview event - PayPal shares are down about 4% to $60.55 in afternoon trading as the company hosts an event to provide an exclusive preview "of the first innovations PayPal and Venmo are piloting and bringing to market this year." The "PayPal First Look" webcast is a keynote hosted by Alex Chriss, PayPal President and CEO, who previously had said in announcing the event: "Twenty-five years ago, at the dawn of the internet, PayPal was created and e-commerce was born - fast forward through decades of innovation and unimaginable growth, PayPal is leading the way to provide safe, secure experiences to customers around the world. I invite you to join us on January 25th to hear about the next chapter of PayPal and how we're going to revolutionize commerce again through AI-driven personalization for both consumers and merchants." Reference Link

12:27 EST Microsoft, Amazon, Alphabet receive order from FTC for AI information - The Federal Trade Commission announced that it issued orders to five companies requiring them to provide information regarding recent investments and partnerships involving generative artificial intelligence companies and major cloud service providers. The agency's inquiry "will scrutinize corporate partnerships and investments with AI providers to build a better internal understanding of these relationships and their impact on the competitive landscape." The compulsory orders were sent to Alphabet (GOOG, GOOGL), Amazon.com (AMZN), Anthropic PBC, Microsoft (MSFT), and OpenAI. The FTC issued its orders under Section 6(b) of the FTC Act, which authorizes the Commission to conduct studies that allow enforcers to gain a deeper understanding of market trends and business practices. "History shows that new technologies can create new markets and healthy competition. As companies race to develop and monetize AI, we must guard against tactics that foreclose this opportunity, "said FTC Chair Lina M. Khan. "Our study will shed light on whether investments and partnerships pursued by dominant companies risk distorting innovation and undermining fair competition."

12:20 EST Sony says 'Horizon Forbidden West' releases on PC March 21 - Sony said that video game "Horizon Forbidden West: Complete Edition" will be releasing for PC on March 21. The 2022 title "Horizon Forbidden West" originally released on PlayStation 4 and PlayStation 5 alone. "Horizon Forbidden West Complete Edition on PC features unlocked frame rates, customizable graphics settings and a broad range of performance-enhancing technologies, including NVIDIA DLSS 3 upscaling and frame generation. AMD FSR and Intel XeSS are also supported," the company said. "For players with high-end hardware and extra headroom, image-enhancing NVIDIA DLAA is also available. The game leverages DirectStorage for quick loading times on PC."

12:00 EST United Rentals rises 12.6% - United Rentals is up 12.6%, or $72.56 to $649.46.

12:00 EST LG Display falls -10.8% - LG Display is down -10.8%, or -56c to $4.58.

12:00 EST MarineMax falls -18.9% - MarineMax is down -18.9%, or -$6.28 to $26.92.

11:02 EST Cintas appoints Beverly Carmichael to board of directors - Cintas Corporation appointed Beverly Carmichael to its Board of Directors, effective immediately. This appointment expands Cintas' Board to 11 Directors. Most recently, she served as the Executive Vice President, Chief People, Culture and Resource Officer at Red Robin Gourmet Burgers.

10:35 EST Eviden, Microsoft announce five-year strategic partnership - Eviden, the Atos Group business leading in digital, cloud, big data, and security, and Microsoft announced a five-year strategic partnership that "significantly expands their existing collaboration with new and innovative Microsoft Cloud and AI-powered solutions for industries." The company stated: "This announcement is part of Eviden's overall partnership & alliance strategy to reinforce and reshape its global partnership network by strengthening its existing partner relationships and fostering new ones. The partnership between Microsoft and Eviden marks a significant milestone in their shared vision to drive digital transformation and empower businesses with advanced technologies. Under this strategic partnership, both companies will co-develop and deploy transformative Data & AI, Copilot, and cloud transformation solutions. By combining Microsoft's expertise in cloud computing and industry-leading technology stack with Eviden's deep domain expertise and customer-centric approach, this collaboration will deliver tailored and innovative solutions to address the complex challenges today's enterprises face. Both organizations are committed to driving an additional $2.8B in Cloud Service Business for Eviden over the next five years."

10:02 EST Qiagen partners with Penn State to advance microbiome sciences - QIAGEN announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences. The university-industry partnership will serve as a beacon for this field by investigating research opportunities that address challenges and research gaps facing the microbiome, which involves the research into a community of microorganisms that can be found living together in any given environment, including the human body. In doing so, this new partnership will provide QIAGEN with a site to support the development of new products as a testing center. It is also designed to provide vital industry research and training opportunities for next-generation scientists. This includes an internship program for graduate students from Penn State at QIAGEN laboratories at the European operational headquarters in Hilden, Germany, and helps them prepare for careers in the biotechnology industry.

10:00 EST Nokia rises 10.7% - Nokia is up 10.7%, or 36c to $3.77.

10:00 EST LG Display falls -9.3% - LG Display is down -9.3%, or -48c to $4.66.

10:00 EST MarineMax falls -14.5% - MarineMax is down -14.5%, or -$4.80 to $28.40.

09:48 EST J-Long Group Ltd trading resumes

09:48 EST Humana falls -11.7% - Humana is down -11.7%, or -$47.28 to $355.12.

09:47 EST ADT Inc. rises 9.9% - ADT Inc. is up 9.9%, or 61c to $6.79.

09:47 EST ResMed rises 10.4% - ResMed is up 10.4%, or $17.81 to $189.59.

09:38 EST J-Long Group Ltd trading halted, volatility trading pause

09:34 EST HNR Acquisition expands oil price hedging program - HNR Acquisition announces the expansion of its oil price hedging program. The hedging strategy of the Company is to maintain a sufficient level of pricing hedges for sales of oil production to cover debt service requirements, and a base level of operating expenses in the event oil prices were to decrease dramatically. The level of pricing hedges for future oil production is targeted to responsibly balance the coverage protection for downward market fluctuations with the potential benefit from upward market fluctuations on current and future-expansion of oil production . HNRA's hedging program is based on a rolling two-year period where the Company reviews, on a rolling three-to-six-month basis, the level that is hedged as additional oil production comes online. If there are dramatic increases in oil prices, the Company will evaluate the benefits of adding more hedges to lock in higher sale prices. The Company uses two types of hedging instruments: swaps where the price is fixed regardless of market price; and collars where the price is subject to a minimum floor/put price and a maximum ceiling/call price. The Company's current hedging portfolio consists of approximately 60% swaps and 40% collars.

09:31 EST Casey's General Stores continues partnership with RAGBRAI - Casey's announced its continued partnership with the world's longest multi-day bicycle touring event, Register's Annual Great Bicycle Ride Across Iowa.

09:26 EST Bit Brother Limited delivers all equipment to second crypto mining farm - "Bit Brother Limited is pleased to announce that all equipment for the operation of our second cryptocurrency mining farm have been delivered. Due to the extremely cold weather in mid-January in Texas some of the equipment delivery which were expected to be delivered before January 10, 2024 were not delivered until January 19, 2024. As of now, the Company has received an initial batch of approximately 1,400 miners, mining containers, transformers, sound barriers and other equipment required for the operation. The 1400 miners have been installed and tested. Majority of the assembly and testing of the other equipment has been completed. We are preparing for the inspection by the Abilene City and issuance of Certificate of Occupancy. Bit Brother expects to receive the Certificate of Occupancy and commencement of Site 2 in early February 2024."

09:18 EST Foresight Autonomous says Rail Vision secures EU approval, certifications - Foresight Autonomous Holdings (FRSX) announced that its affiliate, Rail Vision (RVSN) has received formal certifications for critical European Union railway standards for its Main Line system. This is an important achievement that underscores Rail Vision's dedication to quality, safety, and innovation in the railway technology market. Foresight owns 10.2% of Rail Vision's outstanding share capital.

09:15 EST Northrop Grumman expects to return 'well over 100%' of FCF to holders in 2024 - Plans at least $2B in 2024 share repurchases including initiation of $1B ASR in Q1. Sees FY25 free cash flow $2.85B-$3.25B. Sees FY26 free cash flow $3.1B-$3.5B. Says demand for company's products "remains strong." Says has right portfolio/team to achieve long term targets. Comments taken from Q4 earnings conference call.

09:13 EST SJW Group raises dividend 5.3% to 40c per share - The Board of Directors of SJW Group has declared a quarterly cash dividend of 40c per share payable on March 1 to all shareholders of record at the close of business on Feb. 5 ... The March dividend will represent a 5.3% increase over the dividend paid in December 2023. The 2024 annualized dividend will be $1.60 per share compared with $1.52 per share in 2023. "Today's action by our board to increase the annual dividend demonstrates its continuing confidence in SJW Group's mission and employees," said President, Chief Executive Officer and Chair of the Board Eric W. Thornburg. "Our team of trusted, passionate and socially responsible professionals is committed to delivering life-sustaining, high-quality water and exceptional service while protecting the environment, enhancing our communities and delivering value for shareholders."

09:12 EST LPL Financial: Andrew Kutanovski joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Andrew Kutanovski, CFP, has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reports serving approximately $160 million in advisory, brokerage and retirement plan assets and transitions to LPL from Corebridge Financial, formerly Valic, a subsidiary of AIG. Hailing from the Chicagoland area from a family of financial service professionals, Kutanovski's early exposure to finance fueled his career path. Beginning his journey as a financial advisor in 2016, and achieving his Certified Financial Planner status in 2020, he rapidly distinguished himself as a committed advisor, offering personalized financial planning and investment advisory services. The move to LPL signifies the inauguration of his new independent practice, Kutanovski Wealth Management.

09:10 EST Matterport's Digital Twin Platform helps VRPM design future of workspaces - Matterport demonstrated how Matterport's Digital Twin Platform is being applied to virtual staging for interior design in the commercial real estate sector. Collaborating with Compton, VRPM uses virtual staging within Matterport 3D digital twins to provide potential tenants an authentic sense of what it would be like to inhabit a space. Utilizing Matterport's developer tools, VRPM has created a virtual staging app that seamlessly integrates with 3D scans, enabling collaborative design processes within an immersive digital twin. Virtual staging's future extends beyond just securing tenant leases. It now emphasizes enhancing real estate customer experiences by considering the needs of prospective occupants, such as office furniture requirements or the desire to fully replicate the virtual staging. The accuracy of Matterport's digital twins has enabled VRPM to effectively support Kitt, one of London's leading managed office operators, in staging some of its commercial properties.

09:09 EST Palantir, Carahsoft expand partnership for mission-critical software - Palantir Technologies Canada and Carahsoft Canada, have partnered to expand and accelerate delivery of Palantir's operating systems across the Canadian Public Sector. Building on the success of Palantir's partnership with Carahsoft in the United States, Palantir has authorized Carahsoft, The Trusted Government IT Solutions Provider, to be the sole distributor of the Palantir Platform under the Government of Canada's Software Licensing Supply Arrangement. SLSA is the primary contracting vehicle used by GC departments, agencies, Crown Corporations and other authorized clients to procure enterprise software licenses.

09:07 EST Syla Technologies intends to pay 2023 dividend of Y180 per share - On May 17, 2023, SYLA announced a FY2023 full-year dividend forecast of 140 yen per common share, doubling from FY2022. An interim dividend payment of 70 yen per share was announced on August 16, 2023. Following the announcement of the Revised FY2023 Financial Guidance and today's new FY2024 guidance, the Company intends to pay a FY2023 year-end dividend of 180 yen per common share, thereby increasing the total full-year dividends for FY2023 to 250 yen per common share. The Company intends to propose such FY2023 year-end dividend at the 15th Annual General Meeting of Shareholders scheduled for March 29, 2024.

09:05 EST US Foods in pact with Teamsters Local 705 representing Bensenville, Illinois - US Foods Holding is pleased to have reached a fully recommended tentative agreement with Teamsters Local 705, the union that represents the company's drivers in Bensenville, Ill. The tentative agreement with the union was reached as a result of good faith bargaining efforts. The 5-year agreement provides wage, benefits and healthcare contributions increases that build on the highly competitive offerings drivers in Bensenville, Ill., currently receive, and includes safety enhancements aligned with the very high priority the company places on associate safety. The agreement recognizes the hard-working US Foods Bensenville drivers and enables the company to continue to grow the business as it serves its valued customers in the Chicagoland area. US Foods has a long-standing track record of bargaining in good faith to reach agreements with the union and expects the contract to be ratified on Feb. 3.

09:04 EST Elicio Therapeutics announces preclinical data on TCR-T therapy - Elicio Therapeutics announced the publication of promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research, AACR. These preclinical data demonstrate that Elicio's proprietary "AMP" lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies, TCR-T cells, enhancing anti-tumor function and eradicating solid tumors. Robert Connelly, Chief Executive Officer at Elicio Therapeutics, added, "This study adds to our growing body of preclinical and clinical evidence demonstrating the importance of the lymph nodes and the robust efficacy that our AMP immunotherapy strategy can potentially achieve for patients with solid tumors, both as a monotherapy and in combination with other strategies. The AMP platform provides attractive potential for broad and rapid application to clinical and developmental TCR-T cell programs. We look forward to finding the right partner to advance this promising combination into the clinic for patients with solid tumors."

09:03 EST GM, Honda start commercial production at hydrogen fuel cell joint venture - GM (GM) and Honda (HMC) announced the start of production at their 50-50 joint venture production facility, FCSM, which they call "the first large-scale manufacturing joint venture to build fuel cells." The companies stated: "Together, the two companies also focused on lowering development and manufacturing costs by leveraging economies of scale, advancing the cell design, simplifying supporting auxiliary equipment, utilizing common sourcing, and reducing the use of costly precious metals. Through this collaboration, the new fuel cell systems will be one-third less expensive to make when compared to the cost of the fuel cell system in the 2019 Honda Clarity Fuel Cell... GM and Honda share in the belief that hydrogen and fuel cell technology will play an increasingly important role in meeting a wide variety of zero-emissions energy and mobility needs, and each company has provided further details about their individual hydrogen business strategies." Reference Link

09:03 EST Tyson Foods opens food production facility in Kentucky - Tyson Foods has officially opened its new $355 million food production facility in Bowling Green, Kentucky. Built to support a significant expansion of its bacon production capabilities, the new plant positions Tyson Foods to capitalize on its category leadership and the increasing market for its products. The 400,000-square-foot plant, which represents a significant investment in the local community, is expected to produce two million pounds a week of premium quality Jimmy Dean and Wright Brand bacon retail products and bacon used in foodservice. Bacon represents over $1 billion in sales across retail and foodservice at Tyson Foods. This plant will help the company meet the needs of this category now and as it grows in the future. Located in Warren County's Kentucky Transpark, the new facility will create nearly 450 new jobs in southcentral Kentucky. Tyson Foods is a bacon category leader in foodservice and at retail with Jimmy Dean products representing the fastest-growing retail food brand over the past two years and Wright Brand products rising to the No. 1 consumer choice at retail in the stack category, according to Nielsen data. The new facility represents a significant opportunity for Tyson Foods to further innovate with new bacon flavors, cuts and products such as fully cooked bacon.

09:01 EST American Airlines: FY24 guidance includes potential flight attendant deal

08:56 EST Northrop Grumman sees FY24 free cash flow $2.25B-$2.65B - Sees FY24 CapEx ~$1.8B.

08:50 EST Bright Green to acquire assets from C2 Wellness Corporation - Bright Green announced the agreement to purchase assets from C2 Wellness Corporation, a Wyoming registered company with an address at 30 N Gould St, Ste R, Sheridan, WY, that owns certain platform technologies and associated intellectual property invented and developed by the scientific team of C2. The purchase is for 5 million shares of common stock of Bright Green Corporation payable to all shareholders of C2. The implementation of the transaction has been approved by the board of both companies. The primary assets relate to: Novel cannabinoid molecules and their associated intellectual property; Novel cannabinoid prodrugs, and their associated intellectual property; Novel proprietary cannabinoid formulations, designed to target lymphatic delivery, and their associated intellectual property; Novel proprietary nano-encapsulated cannabinoid formulations, in self dissolving polymers, and their associated intellectual property; and Cannabinoids and cannabinoid pro-drug formulations for topical ocular delivery, and their associated intellectual property. Along with the technology platforms and associated intellectual property come the scientific team of C2 and relationships with universities and a number of renowned academics worldwide.

08:47 EST Hanmi Financial appoints Marasco to board of directors - Hanmi Financial announced that James Marasco has been appointed to the Board of Directors of the Company and the Bank. The addition of Marasco brings the total number of Hanmi Board directors to ten. Marasco was appointed to the Risk, Compliance and Planning Committee and to the Compensation and Human Resources Committee of the Company. With more than 35 years of experience in commercial lending and financial services, Marasco currently is an Executive Vice President and Head of Originations at Gibraltar Business Capital, a national middle market direct lender headquartered in Northbrook, Illinois.

08:46 EST American Airlines has 'modest' aircraft replacement needs, says CFO

08:45 EST BK Technologies receives purchase order for BKR 9000 radios - BK Technologies received a purchase order for 87 of its BKR 9000 multiband radios from the Arkansas Department of Agriculture's Forestry Division. The BKR 9000 is compatible with Arkansas's P25 system, allowing the Forestry Division to significantly enhance efficiency by carrying out their responsibilities using a single radio model across all operations. This is the Forestry Division's first purchase of the BKR 9000.

08:44 EST American Airlines sees 2024 aircraft CapEx about $2.3B

08:42 EST American Airlines planning to grow capacity mid-single digits in 2024 - Sees FY24 CASM ex up 0.5%-3.5%.

08:41 EST Sidus Space's LizzieSat arrives at Vandenberg Space Force Base ahead of launch - Sidus Space is proud to announce that its LizzieSat satellite has arrived at Vandenberg Space Force Base, California. This marks a significant milestone as LizzieSat gears up for its inaugural mission, which is scheduled to launch no earlier than March 2024 on SpaceX's Transporter-10 mission. Upon arrival, the Sidus Space team began final flight preparations ahead of LizzieSat's integration with the launch vehicle. LizzieSat's primary mission involves coincident data collection via multiple sensors to support agriculture, maritime and oil and gas industries. These sensors and receivers include hyperspectral, multispectral, AIS, and optical. Additionally, the Company's onboard FeatherEdge AI, near real-time, actionable intelligence will process the imagery and sensor data offering tailored solutions to customers. Delivery of data is expected to begin 30 days after deployment of LizzieSat. "We are thrilled to reach this crucial stage in our mission. This spacecraft embodies our commitment to providing cutting-edge solutions and valuable data across various industries. The integration of advanced sensors and AI capabilities positions LizzieSat as a pioneering force in the realm of space-based data collection," stated Carol Craig, CEO and Founder of Sidus Space.

08:40 EST Processa Pharmaceuticals announces successful completion of Phase 1b trial - Processa Pharmaceuticals announces the successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine. From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial. The Phase 2 trial will be in advanced or metastatic breast cancer given FDA's agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer. The 5-FU drug exposure for the 18 total patients that received NGC-Cap treatment across four different dosing regimens was 2-10 times that of FDA-approved capecitabine. Sixteen of these patients received at least two cycles of NGC-Cap with the other two patients discontinuing treatment before completing two cycles because of progressing disease. Four of the 16 patients are still receiving treatment in the study. The incidence of myelosuppression in patients on the high dose of NGC-Cap is currently approximately 71%, with more severe myelosuppression occurring in approximately 57% of the patients. The overall myelosuppression incidence rate after patients received the high dose of NGC-Cap is comparable to the 80% rate reported in the capecitabine label. As expected, given the greater 5-FU exposure, the incidence rate of more severe myelosuppression after the high dose of NGC-Cap was greater than the 3% rate reported for capecitabine. For the lower NGC-Cap dose of 150 mg BID, which also has a greater 5-FU exposure than capecitabine, the incidence of myelosuppression and more severe myelosuppression was lower for NGC-Cap compared to capecitabine. Although the primary objective of the Phase 1b trial in patients with advanced gastrointestinal cancer was not to evaluate efficacy, the Phase 1b trial was designed to provide some preliminary data on efficacy. At this time, of the 11 cancer patients receiving one of the two highest doses of NGC-Cap, five have completed an efficacy evaluation at this time, and four of these five patients showed a positive response. One of these four patients had a partial response, and three patients demonstrated stable disease. Two patients receiving the highest dose will potentially become eligible for an efficacy evaluation by the end of the first quarter of 2024. Of the remaining four patients in the two highest doses, two dropped out prior to their evaluation because of disease progression and two dropped out because of side effects.

08:40 EST American sees capacity growth to be balanced between domestic, international - Comments taken from Q4 earnings conference call.

08:39 EST Esgen Acquisition announces updated terms for Sunergy combination - ESGEN Acquisition and Sunergy Renewables announced amended transaction terms for its pending business combination that would result in the combined company becoming a publicly listed company on the Nasdaq Stock Exchange. By the updated terms of the Transaction, ESGEN's sponsor, ESGEN has committed to purchase up to $15 million in Convertible Preferred Equity Securities of which $10 million will be funded at the close of the Business Combination and the remaining $5 million can be funded at the combined company's discretion up to six months after closing. The purchase of the Convertible Preferred Securities will be funded by Energy Spectrum Partners VIII LP. The updated pro forma implied enterprise value of the combined company is expected to be $390 million, and proceeds are expected to be used to fund operations and growth. The amended terms of the Transaction increase the original commitment from Energy Spectrum, in which Energy Spectrum's participation in the common stock PIPE was agreed to be $10 million at $10.00 per share. In addition, the Sponsor and other insiders agreed to forfeit a total of 2.9 million founder shares at the closing, which will leave 4.0 million founder shares remaining. The amended terms of the Transaction also provide that 500,000 additional founder shares will be forfeited if the Convertible Preferred Securities are redeemed or the Sponsor elects to voluntarily convert them, in each case, within 2 years of closing. Finally, all of the outstanding private placement warrants held by the Sponsor and other insiders will be cancelled at the closing of the Transaction. After the Transaction, the Board of Directors of the combined company will include representatives from both Sunergy and ESGEN. The Board of Directors of ESGEN and the board of managers of Sunergy have unanimously approved the Transaction. The Completion of the proposed Transaction is subject to customary closing conditions and is anticipated to occur in the first half of 2024.

08:38 EST Warburg Pincus, TA Associates to sell Procare Solutions to Roper for $1.86B - Warburg Pincus announced the signing of a definitive agreement to sell Procare Solutions to Roper Technologies, for a total enterprise value of $1.86B. TA Associates, a global private equity firm, also sold its minority interest in Procare as part of the transaction. Procare is a provider of center management software and integrated payment processing solutions to child care centers in the US, enabling administrators to maintain a core system of record and workflow for operational, compliance, staffing, billing, and accounting functions. The transaction is expected to close in the first quarter of 2024, subject to regulatory approvals and customary closing conditions.

08:37 EST Clean Energy Technologies continuing normal operations amid stock volatility - Clean Energy Technologies addresses stakeholders regarding recent stock fluctuations. The company said, "CETY is currently operating under normal conditions and our dedicated team continues to work diligently to meet our strategic goals. CETY is on track and committed to deliver the highest standards of quality and services to our customers. CETY is not aware of any new material developments or pending announcements concerning its business operations that may be contributing to the recent volatile market activity in the trading of its common stock. In light of recent stock fluctuations, CETY wants to emphasis and assure all our stakeholders that the market volatility does not reflect the overall health and stability of the Company. It is important to remember that temporary fluctuations in price do not reflect the underlying strength and long-term prospects of CETY. As a responsible and transparent organization, CETY believes in providing accurate and timely information to all our stakeholders. CETY encourages you to focus on the long-term value and potential of the company rather than short-term market fluctuations. CETY is confident in our business strategy and remain steadfast in our commitment to creating value for our shareholders, customers, employees, and partners."

08:36 EST Warburg Pincus, TA Associates to sell Procare Solutions to Roper for $1.86B

08:25 EST Catheter Precision enters distribution agreement in Turkey - Catheter Precision, has signed a new distributor for Turkey for VIVO, a non-invasive 3D localization system. Ege Artimi, located in Izmir, Turkiye, was founded in 2014 and specializes in importing and providing clinical support to cardiology products.

08:23 EST SOBR Safe signs fourth behavioral health provider - SOBR Safe signed its fourth behavioral health provider. Based in Southern California, the customer operates four facilities and an outpatient program. The customer is initially installing SOBRcheck in one facility for point-of-care screening, and is evaluating the technology for expansion into its remaining facilities. The customer is also evaluating the wearable band SOBRsure for continuous monitoring in an outpatient scenario.

08:20 EST Kronos implements new leadership structure, eliminates CMO, CSO, COO roles - Kronos Bio announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio's current operating needs. As part of this effort, Kronos Bio has eliminated three executive officer roles including the Chief Medical Officer, Chief Scientific Officer, and Chief Operating Officer and General Counsel. As a result, Jorge DiMartino, M.D., Ph.D., Christopher Dinsmore, Ph.D., and Barbara Kosacz, J.D., will be departing the Company. To ensure a smooth transition, they will remain with the Company through February 16, 2024. All three executives will remain strategic advisors to Kronos Bio. The Executive Leadership team, reporting to Dr. Bischofberger, now includes: Charles Lin, Ph.D., Senior Vice President, Research and Development; Elizabeth Olek, DO, Senior Vice President, Clinical Development; Rocio Martin Hoyos, Senior Vice President, Corporate Strategy and Portfolio Management; Allison Frisbee, Senior Vice President, Corporate Operations and Legal/ Each of these leaders brings robust and diverse experience with a focus in oncology. Kronos Bio has expected cash runway into 2026. Information regarding severance and related benefits for those employees whose roles have been eliminated are set forth in a Current Report on Form 8-K, being filed with the Securities and Exchange Commission approximately concurrently with the issuance of this press release. After realizing these one-time termination costs, Kronos Bio anticipates that it will realize financial savings from its new operating model.

08:18 EST Woodward announces up to $600M three-year stock repurchase program - Woodward announced that its Board of Directors authorized a three-year stock repurchase program, under which up to $600 million in Woodward stock may be repurchased in the open market and private transactions. This new program replaces the previously authorized two-year $800 million repurchase program, which was initially authorized in January 2022, and under which the company repurchased approximately $572 million in stock.

08:16 EST Enviri and Veolia North America in hazardous waste treatment deal, no terms - Clean Earth, a division of Enviri, and Veolia North America, have executed a long-term collaborative agreement for significant incineration capacity at the new state-of-the-art thermal facility in Southwest Arkansas. The five-year agreement, structured to provide guaranteed access for Clean Earth by Veolia, is a first-of-its-kind in the industry and a positive advancement for the waste management industry and customers as the new facility, opening in 2025, will provide much-needed additional capacity...Veolia's new facility will be powered by local decarbonizing energy generated directly on-site, North America's first for a hazardous waste plant. The power will be supplied by capturing waste heat recovered from a boiler and steam turbine and generating five megawatts of on-site solar power per hour, creating a more sustainable option for the marketplace and benefiting consumers and the public. A plan to reforest nearly 1,500 acres surrounding the property will sequester carbon emissions, provide protection for local habitat, and prevent erosion. Veolia North America will increase waste treatment access for Clean Earth throughout 2024 to ramp up activities for a smooth transition in 2025

08:14 EST Bionano Genomics announces publication of study on OGM - Bionano Genomics announced a peer-reviewed publication in Cancers from a team of cancer researchers primarily at the NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute and Scripps MD Anderson in La Jolla, California. The publication describes what could be the first study to use optical genome mapping for the discovery of structural variants that drive drug resistance and sensitivity in cancer. Study Design: Genome Variation Signatures. The study compared genome variation signatures obtained from the leukemia samples by OGM and by classical cytogenetic methods including karyotyping and fluorescence in situ hybridization. Drug Library. The study used a broad collection of 120 cancer drugs based on the Oncology Drug Library and the FDA-approved oncology collection drugs from the NCI's Developmental Therapeutics Program. Drug Resistance & Sensitivity Assay. The study used a cell viability and drug screening assay based on growing leukemia-enriched cell collections in the presence of different concentrations of drug agents to measure cell viability. Key Findings: Overall, the study shows that OGM for SV detection combined with drug sensitivity data for the same samples is a useful approach to identifying potentially pathogenic SVs that may be drivers of drug sensitivity or resistance. Key findings are as follows: OGM detected all SVs that had been observed using classical cytogenetic methods as well as multiple additional variants that were not previously reported; BCR-ABL1 translocated leukemia samples are sensitive to the tyrosine kinase inhibitor Nilotinib, as expected, but exhibit resistance to proteasome inhibitors; Drug sensitivities associated with previously unreported genomic rearrangements were revealed; Leukemia samples with KMT2A translocations are associated with drug sensitivities to the microtubule disruptors Paclitaxel and Cabazitaxel and resistance to Bcl-2 family inhibitors; Chemosensitivity associations with SVs detected by OGM are able to reveal several potential new treatment strategies for leukemia

08:12 EST NV5 Global announces acquisition of CHW Professional Consultants - NV5 Global announced that it has acquired CHW Professional Consultants, CHW, a leading provider of engineering and infrastructure consulting services in Florida. CHW's 130 employees specialize in surveying and mapping, civil and transportation engineering, landscape architecture, program management, planning, and environmental services. The company's target sectors include transportation authorities, utilities, healthcare, educational institutions, and private sector development. "The acquisition of CHW strengthens our ability to support infrastructure and development in the fastest growing regions of Florida and gives NV5 access to premier public and private sector clients," said Dickerson Wright, PE, Chairman and CEO of NV5. "CHW's technical expertise and strong leadership team will deliver expanded services to our clients and enhanced drivers for accelerated organic growth throughout the state."

08:10 EST Super League implements organizational enhancements - Super League announces the implementation of important organizational enhancements. This strategic move aligns with the escalating demand from global brands seeking Super League's deep-rooted expertise and innovative approaches to engagement within emerging critical segments of the digital world. With average daily time spent by Gen Z on Roblox eclipsing time on Tik Tok, immersive web experiences and open gaming platforms have become pivotal for brands to achieve business growth. By responding to market needs, Super League ensures its continued ability to set the benchmark for excellence as a strategist, builder, and marketing and operating partner - shaping the future of brand engagement and immersive commerce for young generations. Through learning and evolution, Super League focused on optimizing the company's workflows, enhancing internal and external communications, and curating its team structure and responsibilities. These adaptations are a testament to the company's significant growth, having successfully executed nearly 200 immersive branded programs and campaigns in the past year. By elevating the company's organizational architecture, Super League's breadth of capabilities and commitment to innovation are woven more firmly into the fabric of every team, from strategy and creation to execution and measurement, all to ensure success for the company's marquee roster of partners. The reimagined Client Partnerships team now champions brand and agency relationships, driving revenue through strategic alliances and multi-faceted partnerships. Concurrently, the Brand Strategy arm delves into deepening client connections, and building bespoke programs to resonate with partner ambitions. Program Management ensures seamless execution and insightful reporting, encapsulating the lifecycle of each project. The team behind Marketing Insights crafts compelling narratives, deriving strategies grounded in a solid foundation of data and consumer understanding. These departments are led by an all-female team of veteran digital executives, who collectively bring multiple decades of client service, strategy, partnership and execution experience to their roles. The Creative and Studio teams will continue their work in building premium immersive experiences, nurtured by an unparalleled network of creators and developers. On Roblox alone, experiences from creators in Super League's network reach more than 140 million monthly active users. Together, these enhancements reflect Super League's promise to bring powerful ideas to brands looking to enter and grow in the space, and then backstop the ideas through scalable and enduring end-to-end solutions.

08:10 EST Ocular Therapeutix announces FDA agreement to amend SPA for AXPAXLI - Ocular Therapeutix announced that the U.S. Food and Drug Administration, FDA, has agreed to a Special Protocol Assessment, SPA, Agreement Modification for the Company's pivotal Phase 3 SOL clinical trial of AXPAXLI for the treatment of wet age-related macular degeneration. The SPA Agreement Modification enables the trial to include treatment-naive wet AMD subjects with visual acuity of approximately 20/80 or better at the initial screening visit. After two aflibercept injections in the screening period, eligible participants would need to gain at least 10 ETDRS letters from the initial screening visit to Day 1 or achieve a visual acuity of approximately 20/20 or better at Day 1, in addition to satisfying other criteria, to qualify for enrollment in the trial. The SPA Agreement Modification also allows the pivotal trial to move forward, evaluating AXPAXLI with a single optimized implant with a drug load of 450 microgram of a more soluble form of axitinib.

08:09 EST Organovo presents FXR314 3D human tissue model findings - Organovo announced the presentation of preclinical data related to the company's FXR314 development program in its proprietary 3D human tissue models of Crohn's disease and ulcerative colitis at the Crohn's and Colitis Congress being held January 25-27, 2024 in Las Vegas, Nevada. "There is a critical need for novel approaches to treat inflammatory bowel disease that extend beyond modulating the immune response targeted by current pharmacological therapies. These data underscore the potential of FXR314 as a unique treatment approach to IBD given its demonstrated multifaceted activity profile, especially in directly improving the intestinal barrier function and controlling fibrosis," said Dr. Fabrice Piu, Vice President, Research & Development. The presentation highlights preclinical data characterizing the activity of FXR314 in 3D models of human Crohn's disease and ulcerative colitis. FXR314 broadly improved measures of epithelial barrier function in a subset of donors, and fibrotic markers in all Crohn's disease donors. In ulcerative colitis, FXR314 improved epithelial barrier function and fibrotic activity in all donors. Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 2024, with targeted completion in 2025. The drug's additional promise in liver fibrosis and NASH makes it a strong candidate for development in that.

08:08 EST Concord Acquisition Corp III receives NYSE notice of non-compliance - Concord Acquisition Corp III announced it had received a notification dated January 19, from the New York Stock Exchange informing the Company that, because the number of public stockholders is less than 300, the Company is not in compliance with Section 802.01B of the NYSE Listed Company Manual. The Listing Rule requires the Company to maintain a minimum of 300 public stockholders on a continuous basis. The Notice specifies that the Company has 45 days to submit a business plan that demonstrates how the Company expects to return to compliance with the Listing Rule within 18 months of receipt of the Notice. The Company plans to promptly submit a business plan that demonstrates how the Company expects to return to compliance with the Listing Rule within 18 months of receipt of the Notice. The Notice has no immediate impact on the Company's common stock, and provided the NYSE approves the plan, the Company's common stock will continue to be listed and traded on the NYSE during the 18-month period, subject to the Company's compliance with other NYSE listing standards and periodic review by the NYSE of the Company's progress under the plan.

08:07 EST Prime Medicine receives up to $15M from CF foundation - Prime Medicine announced that the Cystic Fibrosis Foundation has agreed to provide the Company with up to $15 million to support the development of Prime Editors for the treatment of Cystic Fibrosis, CF. Funding from the CF Foundation will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE. "Leveraging our Prime Editing technology, we hope to create a one-time, non-viral therapy, which can precisely correct the underlying genetic mutation that causes CF and potentially offer the first cure for this progressive, devastating disease," said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. "We are pleased to advance this work together with the CF Foundation, an organization devoted to delivering transformative therapies - and one day a cure - that will allow all people with CF to live longer, healthier lives, with tremendous reach across the clinical, academic and patient communities. We believe their many resources and learnings will allow us to accelerate our ongoing efforts, investing in delivery optimizations and early research that could, if successful, allow many more people to achieve normal, healthy lung function."

08:04 EST Southern Company's Alabama Power collaborates with Eco Material Technologies - Eco Material Technologies announced a collaboration with Alabama Power, a subsidiary of Southern Company, to harvest millions of tons of stored ash from Plant Barry, a coal- and natural gas-fired electrical generation facility in Bucks, Alabama. This project is the third such harvesting plant with Southern Company, following Plants Bowen and Branch in Georgia. Under the agreement, Eco Material will harvest more than 700,000 tons of stored ash per year from the plant. The effort will remove and beneficially use millions of tons of ash over the term of the agreement.

07:55 EST Energy Vault in new 10 year licensing deal with SADC region - Energy Vault Holdings announced that it has signed a new licensing and royalty agreement in the Southern African Development Community, SADC region. The agreement was executed in Q4 2023 with Gravity Energy Storage Solutions, a consortium company focused on energy storage deployments in Southern Africa, and includes one of the largest listed engineering, procurement and construction EPC companies in the region WBHO who will support all engineering, procurement and construction activities, as well as pan-African project engineering group iX Engineers and commercial developer Sizana Solutions ..The multi-year agreement is expected to facilitate multi-gigawatt hours GWh's of long duration Energy Vault GESS deployments to contribute to the SADC region's energy storage needs, estimated to reach over 125 GWh by 2035. .. Under the terms of the agreement, GESSOL will have exclusive rights to deploy Energy Vault's portfolio of gravity energy storage technology and VaultOS throughout the SADC region, a 16 member-state regional economic community with a mission to promote sustainable and equitable economic growth and socio-economic development. SADC's member states are comprised of: Angola, Botswana, Comoros, Democratic Republic of Congo, Eswatini, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, United Republic Tanzania, Zambia and Zimbabwe.

07:52 EST Usana manufacturing facility receives GFSI certification from SQF - Usana earned a Global Food Safety Initiative - GFSI - certification of its foods manufacturing facility through the Safe Quality Foods - SQF - program. The certification pertains to Usana's enrobed snack bars and drink mix powders. In 2019, USANA opened a new foods facility next door to the company's main office and manufacturing hub in Salt Lake City, Utah. This ~43,000-square-foot manufacturing plant handles USANA's bar, gusset, single-serve, and powder blending production. GFSI is a coalition formed in 2000 made up of retailers, scientists, and other members of the Consumer Goods Forum from 70 countries around the world. The goal of GFSI is to reduce recalls and provide safer, more reliable products to consumers by defining elite industry standards. SQF is a food safety standard recognized by GFSI. This recognition means companies implementing SQF can demonstrate compliance with GFSI's global standards, enhancing their credibility and market access.

07:49 EST American Airlines has 20 MAX 8s planned for delivery this year, CEO tells CNBC

07:47 EST American Airlines CEO tells CNBC that Boeing needs to 'get their act together' - American Airlines CEO Robert Isom is speaking on CNBC.

07:46 EST Accuray Cybeknife system selected by Radiosurgery Center in Seattle - Accuray announced that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife S7 System, the hospital's second CyberKnife radiation delivery device purchase.

07:43 EST National Energy Services announces inauguration of 'Carbon Light' brine plant - National Energy Services Reunited announced the inauguration of its flagship 'Carbon Light' oilfield brine plant in North Rumaila. The project and opening ceremony were conducted with BECL operating Rumaila Operating Organization in Iraq. NESR undertook the investment in the 'Carbon Light' brine plant as part of an existing, long-term brine supply agreement to support ROO operations in North Rumaila. Leveraging partner Clean TeQ's continuous ion filtration and high-recovery reverse osmosis technology, the first such deployment globally in the upstream energy sector, NESR & BP endeavor to re-envision the way that oilfield brine is manufactured, and also substantially reduce water waste and the carbon footprint associated with brine supply.

07:38 EST Wiley says confident will meet medium-term targets amid recent reorganization - Wiley will host its Investor Update on Thursday.. at 10 am E.T. to discuss the company's business and financial outlook. This virtual event will feature presentations by key members of the executive management team and focus on Wiley's execution on the following priorities: Wiley's recent reorganization around its Research & Learning core to better leverage its competitive advantage, drive scale, and improve operating and capital efficiency. The implementation of a 'focus and optimize' strategy to deliver healthy revenue growth and material margin improvement in Fiscal Years 2025 and 2026. Wiley will share its medium-term targets for revenue growth, Adjusted EBITDA margins, and Free Cash Flow. "We continue to execute well on our value creation plan to make Wiley a stronger and more profitable company, giving us confidence in our ability to meet our medium-term targets and deliver sustained long-term success," said Matthew Kissner, Wiley's interim president and CEO. "Our renewed focus on our core presents exciting opportunities to grow by leveraging our must-have content and solutions for high-demand areas of the knowledge economy."

07:37 EST Else Nutrition to launch toddler products, RTD Kids Shakes in supermarket chain - ELSE NUTRITION HOLDINGS announced the launch of its toddler products and Ready-to-Drink Kids Shakes in both Chocolate and Vanilla flavors in a prominent supermarket chain with over 100 stores throughout the Northeast.

07:36 EST Knight Therapeutics, Amneal Pharmaceuticals enter license agreement - Knight Therapeutics (KHTRF) entered into an exclusive license agreement with Amneal Pharmaceuticals (AMRX), granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America. IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules designed for the treatment of Parkinson's disease. Financial terms of the agreement were not disclosed. IPX203 contains immediate-release granules and extended-release coated beads. The IR granules consist of CD and LD, with a disintegrant polymer to allow for rapid dissolution. The ER beads consist of LD, coated with a sustained release polymer to allow for slow release of the drug, a mucoadhesive polymer to keep the granules adhered to the area of absorption longer, and an enteric coating to prevent the granules from disintegrating prematurely in the stomach. IPX203 was studied in the RISE-PD clinical study which was a 20-week, randomized, double-blind, double-dummy, active-controlled, phase 3 clinical trial with 630 patients. The RISE-PD study met its primary and secondary endpoints and showed that treatment with IPX203 demonstrated statistically significant improvement in daily "Good On" time with fewer doses of IPX203 compared with immediate-release carbidopa-levodopa, with IPX203 dosed a mean three times per day vs 5 times per day for immediate-release carbidopa-levodopa.

07:34 EST Agrify announces results of reconvened annual meeting - Agrify Corporation announced that the shareholders of the Company approved an amendment to the Company's Articles of Incorporation to increase the number of authorized shares of the Company's common stock from 10,000,000 to 35,000,000, that all its outstanding debt held by CP Acquisitions, an entity affiliated with Raymond Chang, the CEO of the Company and a member of the Board of Directors, and I-Tseng Jenny Chan, a member of the Board, has been consolidated under a single convertible note and approximately $3.9 million of the outstanding debt has been converted into equity at a conversion price per share equal to $1.46, or 212% premium to the latest closing price, and that its prior secured lender has exercised 2,475,629 of the warrants previously issued in October 2023 on a cashless basis for a net issuance of 2,473,542 shares of common stock, thus greatly reducing the number of outstanding warrants. The Company's Annual Meeting of Stockholders on January 8, 2024 was adjourned until January 22, 2024, only with respect to the proposal to approve the Charter Amendment, owing to Item 3 receiving less than the affirmative vote of a majority of the Company's outstanding common stock as of the record date of December 6, 2023, which was the required minimum vote to approve the Charter Amendment. At the Reconvened Meeting, shares representing approximately 51.6% of the outstanding shares of common stock as of the record date were voted in favor of the Charter Amendment, representing approximately 94.6% of votes cast on the proposal, resulting in the Charter Amendment being approved. The Charter Amendment will provide the Company with a number of shares of common stock so that common stock can be issued in connection with conversion of the Restated Note into equity, among other things. In addition, the New Lender, which previously purchased from the Prior Lender the Senior Secured Note issued by the Company to the Prior Lender on August 19, 2022 and the Senior Secured Convertible Note issued by the Company to the Prior Lender on March 10, 2023, and to which the Company previously issued a junior secured promissory note with a maximum principal amount of $4,000,000, entered into a consolidation, amendment and restatement of the Convertible Note with the Company to consolidate the outstanding principal and interest due under the Junior Secured Note and the Exchange Note into the Convertible Note and to amend and restate the Convertible Note consistent with the terms contained in the proposal approved by the stockholders of the Company at the Annual Meeting, with an outstanding principal amount of approximately $18.9 million at the time of issuance of the Restated Note. Immediately following the execution of the Restated Note, the New Lender elected to convert approximately $3.9 million of outstanding principal into an aggregate of 2,671,633 shares of common stock, at a conversion price of $1.46 per share, and assigned its rights to receive such shares to entities affiliated with Mr. Chang and Ms. Chan. Concurrently, GIC Acquisition, another entity affiliated with Mr. Chang, agreed to increase the principal amount under its previously-issued junior secured note from $0.5 million to $1 million. On January 22, 2024, pursuant to notices of exercise received from the Prior Lender, the Company issued an aggregate of 2,473,542 shares of common stock to the Prior Lender upon the cashless exercise of two warrants issued to the Prior Lender on October 27, 2023. The issuance of the Warrant Shares represents the full exercise of the Abeyance Warrant as described in the Company's Current Report on Form 8-K filed on October 30, 2023 and the partial exercise of the Exchange Warrant as described in the October 30 Form 8-K, which remains exercisable for up to 659,669 shares of common stock, subject to adjustment pursuant to its terms. The consolidation of the outstanding debt held by the New Lender into the Restated Note and the conversion of some amount of the debt thereunder, together with the reduction in the number of outstanding warrants held by the Prior Lender is expected to result in a reduction in liabilities on the Company's balance sheet, which the Company believes will help it to regain compliance with Nasdaq's Listing Rule 5550(b)(1), which requires that listed companies maintain a minimum of $2.5 million in stockholders' equity.

07:32 EST InflaRx announces initiation of its commitment program for GOHIBIC - InflaRx Pharmaceuticals, a subsidiary of InflaRx N.V., announced that the Company has launched The InflaRx Commitment Program. Pursuant to the Commitment Program, the cost of GOHIBIC will be refunded for up to six administered inpatient doses to institutions that meet the eligibility requirements, for patients who were administered GOHIBIC in line with its EUA and who died due to COVID-19 in the intensive care unit. In April 2023, the U.S. Food and Drug Administration, FDA, issued an EUA for GOHIBIC for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of the patient receiving invasive mechanical ventilation, IMV, or extracorporeal membrane oxygenation, ECMO. While GOHIBIC has been FDA authorized, it is not FDA approved for this use. Prof. Niels Riedemann, Chief Executive Officer, and Founder of InflaRx, commented: "COVID-19 continues to take far too many lives. Despite this unacceptable situation, patients do not always have access to approved or authorized treatment options. With today's announcement, we are demonstrating our strong commitment to help make GOHIBIC available for the most affected COVID-19 patients as a potential life-saving therapy. There are currently no approved or authorized alternatives to GOHIBIC, and we believe that all eligible patients and the physicians responsible for their care should have access to this treatment."

07:28 EST Laser Photonics receives order from Karavan Trailers for CleanTech laser system - Laser Photonics received an order from Karavan Trailers for its CleanTech LPC-1500-CTHD laser cleaning system.

07:26 EST Humana anticipates $1B in share repurchases in 2024 - Approximately $400M of which has been completed to date.

07:20 EST Tilray's Breckenridge Brewery releases 'Juicy Oasis Fruited Hazy IPA' - Breckenridge Brewery introduces its latest beer - the Juicy Oasis Fruited Hazy IPA. Kicking it up a notch with a fruit-forward taste and powerful 9.6% ABV, this beer is bursting with the smooth blend of Pineapple and Passionfruit and uses real agave nectar - perfect for both the avid hazy IPA enthusiast and the fruit-minded beer drinker. The launch of Juicy Oasis builds on Breck Brew's success with Hazy IPAs and is a new take on last year's Imperial Watermelon Lime Agave Wheat brew now with a more luscious tropical essence.

07:19 EST Draganfly enrolls Commander 3XL platform in the Green UAS program - Draganfly announces it has enrolled the Commander 3XL platform in the Green UAS program, a new program administered by the Association for Uncrewed Vehicle Systems, AUVSI. In this initiative, coupled with the associated Trusted Cyber program, Draganfly aims to achieve certification for the Commander 3XL platform, ensuring it meets the most stringent cybersecurity and supply chain standards specified in the National Defense Authorization Act, NDAA. Draganfly's engagement in the Green UAS program is geared towards fast-tracking the endorsement of the Commander 3XL platform among commercial entities and state and federal government agencies, including the Departments of Defense and Homeland Security. "The Commander 3XL from Draganfly, recognized for its dependability, is now actively deployed across the globe by premier commercial users and governmental bodies," said Cameron Chell, CEO and President of Draganfly. "Engaging in the Green UAS program allows us to underscore our system's advanced nature and high quality. This initiative is crucial for facilitating its broader acceptance by American government agencies in areas such as defense, homeland security, and public safety, where stringent security and trustworthiness are paramount."

07:18 EST Bruker announces agreement to acquire Chemspeed, no terms - Bruker announced a definitive agreement for the acquisition of Chemspeed Technologies , a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. Chemspeed's modular, compact FLEX automation workstations enhance chemical and materials science R&D and lab productiviity.Strategically, Chemspeed's automation solutions strengthens Bruker's Project Accelerate 2.0 initiative 'Assays, Software and Aftermarket'. The closing of the transaction is expected to occur in the first half of 2024, subject to regulatory reviews. Financial details of the transaction were not disclosed. In 2023, Chemspeed generated revenues greater than $50M, and Chemspeed was profitable.Specifically, Chemspeed offers a portfolio of flexible automation modules, ranging from bench-top workstations to integrated automated R&D workflows, which can transform R&D productivity in industries such as pharmaceuticals, biotech, chemicals, cleantech, materials, cosmetics and food. Chemspeed automation is used every day in top R&D and QC laboratories globally, setting standards in lab automation. Chemspeed also offers compliance-ready workflow solutions to automate and digitalize R&D and QC in regulated environments, ensuring data integrity, traceability and quality.

07:17 EST Guru Organic Energy expects momentum in net revenue growth to continue - At this time, management currently expects the momentum in terms of net revenue growth and loss reduction to continue in the short to medium term.

07:16 EST CPI Card Group names John Lowe President and CEO - CPI Card Group announced John Lowe has been named its new President and Chief Executive Officer and appointed to the Company's Board of Directors, effective immediately. Lowe succeeds outgoing President and Chief Executive Officer Scott Scheirman, who had previously announced his intention to retire in early 2024. Lowe has been with CPI Card Group since 2018, most recently as Executive Vice President, End-to-End Payment Solutions since late 2022. In this role he was responsible for a significant majority of the Company's revenues and operations. He previously served as the Company's Senior Vice President and General Manager, Secure Card, beginning in 2021, and was the Company's Chief Financial Officer from 2018 through 2021.

07:14 EST Zentalis appoints Hausman as CMO, Rasbach as CBO - Zentalis Pharmaceuticals (ZNTL) announced that Diana Hausman, M.D., a member of Zentalis' Board of Directors, was appointed as Chief Medical Officer, CMO, and Kyle Rasbach, Ph.D., Pharm.D., was appointed as Chief Business Officer, CBO. Dr. Hausman is an oncologist with over a decade of experience as a Chief Medical Officer, having previously served in the role at Link Immunotherapeutics, Lengo Therapeutics, Zymeworks (ZYME), and Oncothyreon. Dr. Hausman will succeed Carrie Brownstein, M.D., who is stepping down for personal reasons. Dr. Brownstein will remain with Zentalis as a consultant for a transitional period. Dr. Rasbach comes to Zentalis from Eventide Asset Management, where he was a Portfolio Manager for Eventide's healthcare and life sciences strategies, a Managing Director for Eventide Ventures, and a Senior Research Analyst for other Eventide investments.

07:12 EST Repare Therapeutics earns $40M milestone payment from Roche for TAPISTRY trial - Repare Therapeutics (RPTX) announced that, under its worldwide license and collaboration agreement with Roche (RHHBY) for the development and commercialization of camonsertib, it has earned a $40M milestone payment from Roche upon dosing of the first patient with camonsertib in Roche's TAPISTRY trial. TAPISTRY is a Phase 2, global, multicenter, open-label, multi-cohort clinical trial designed to evaluate the safety and efficacy of targeted therapies or immunotherapy in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations. In October, Roche also enrolled the first patient in a camonsertib-based arm in its Phase 1b/2 clinical trial of multiple immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer. The TAPISTRY and MORPHEUS trials are actively enrolling patients. In collaboration with Roche, Repare is continuing to conduct tumor specific expansions in the ATTACC trial to support future clinical development for camonsertib + PARP inhibitor combinations. Under the terms of its collaboration with Roche, Repare received a $125M upfront payment in July 2022, as well as $13.6M in additional payments, and is eligible to receive up to $1.2B in potential clinical, regulatory, commercial and sales milestone payments, and royalties on global net sales ranging from high-single-digits to high-teens. The collaboration also provides Repare with the ability to opt-in to a 50/50 U.S. co-development and profit share arrangement, including participation in U.S. co-promotion if U.S. regulatory approval is received. If Repare chooses to exercise its co-development and profit share option, it will continue to be eligible to receive certain clinical, regulatory, commercial and sales milestone payments, in addition to full ex-U.S. royalties.

07:12 EST Panbela Therapeutics exceeds 50% enrollment for its ASPIRE trial - Panbela Therapeutics announced it has reached 50% enrollment for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. "We're thrilled to have surpassed 50% enrollment for the ASPIRE trial and to be moving faster than originally projected," said Jennifer Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "As we have reached the near full complement of sites open and enrolling, we have seen a steady cadence of enrollment, expecting full enrollment to be completed by Q1 2025. We are looking forward to the interim data analysis based on overall survival in mid-2024."

07:09 EST Humana falls 12% to $352.81 after weak FY24 adjusted EPS outlook

07:08 EST American Airlines reports Q4 operating margin ex-items 5.1% - For the full year, American produced record revenue of nearly $53 billion. In the fourth quarter, the company generated revenue of more than $13 billion and an operating margin of 5.0% on a GAAP basis. Excluding the impact of net special items1, American produced an operating margin of 5.1% in the fourth quarter, exceeding the high end of the company's prior guidance. These results were driven by continued strong demand for American's product, record revenue from its travel rewards program, strong operational performance and effective cost control.

07:06 EST Centogene, The Lab announce rare disease research collaboration - Centogene and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine today announced a strategic research collaboration to improve health outcomes for rare disease patients by accelerating and de-risking drug discovery and clinical development. As part of the collaboration, CENTOGENE and the Lab will leverage the CENTOGENE Biodatabank, which contains over 70 million unique genetic variants collected from more than 800,000 patients from over 120 countries - providing valuable and unparalleled insights into the role that specific genes play in disease. Together, CENTOGENE and the Lab will jointly agree on future research projects that will integrate multiomics and bioinformatics to analyze this highly diverse data to discover and validate novel genetic and biochemical targets that can be used for future development of rare disease therapies. By proving and validating the relevance of a target to disease and that modulating it will have the desired outcome, drug discovery and development can be significantly accelerated and de-risked. Specific targets of the collaboration have not been disclosed.

07:03 EST American Airlines reduces total debt by $3.2B in 2023 - Reduced total debt by $3.2 billion in 2023. The company is more than 75% of the way to its 2025 total debt reduction goal.

06:52 EST Babcock & Wilcox awarded 75MW of solar EPC contracts in Pennsylvania - Babcock & Wilcox subsidiary Babcock & Wilcox Solar Energy has been awarded contracts by Cypress Creek Renewables to implement three utility-scale photovoltaic solar power installations totaling 75 megawatts in western Pennsylvania. When complete, each solar installation will be capable of generating approximately 25 megawatts of clean, zero-carbon energy - enough to power around 10,000 homes - while creating nearly 90 construction jobs for the duration of the projects. Site work for the first project began in November 2023, and work for the second and third projects is scheduled to begin in March 2024. All three facilities are anticipated to be operational in 2024.

06:42 EST Humana: Higher Medicare Advantage medical costs to persist in 2024 - Affirms 2024 individual Medicare Advantage annual membership growth of approximately 100,000 or 1.8%.

06:41 EST Applied Industrial Technologies increases dividend to 37c per share - Applied Industrial Technologies approved an increase in the quarterly cash dividend to 37c per common share, payable on February 29th to shareholders of record on February 15th.

06:37 EST Humana names David Dintenfass as President of Enterprise Growth - Humana announced that it has named David Dintenfass as President of Enterprise Growth. In this new role, Dintenfass will have responsibility for leading the company's growth plan with a primary focus on customer acquisition, retention, and experience. The creation of this position, and its emphasis on the customer and digital experience, will help Humana deliver on its long-term strategy and maximize long-term growth within the Medicare Advantage market. By 2030, one in five Americans is projected to be 65 years old or older, and Humana is the second largest MA provider in the U.S. with more than 5 million customers today.

06:26 EST Parsons wins $115M contract from U.S. Department of Labor - Parsons announced that the company was selected by the United States Department of Labor Job Corps Acquisition Services to assist with planning, management, and oversight of the Job Corps Facilities Program. Parsons is the sole awardee on the over $115M ceiling value contract, which includes a base performance period of one year and four one-year option periods. Parsons' scope includes project management and oversight support for the Job Corps' Facilities Program. This award continues a contract that the company has held since 2013.

06:08 EST Dow Inc. expects softness in industrial, durable goods demand to continue in Q1 - "In 2024, we will maintain our commitment to financial and operational discipline as we continue to navigate dynamic market conditions. While we expect softness in industrial and durable goods demand to continue in the first quarter, we are encouraged by early positive signals in areas including construction, automotive and consumer electronics," said Fitterling. "Our strong balance sheet and cash generation give us the flexibility to cover all of our capital allocation priorities as we progress through the economic cycle and advance our Decarbonize & Grow and Transform the Waste strategies. These projects are expected to deliver more than $3 billion in underlying earnings annually by 2030. Our cost-advantaged footprint, leadership in attractive end markets, and strategic growth investments position the Company well to create long-term value."

06:04 EST Liquidia provides update on NDA for YUTREPIA - Liquidia announced that the U.S FDA provided an update on its review of the New Drug Application for YUTREPIA inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The FDA informed the company that it is confirming the process for adding the PH-ILD indication as an amendment to the NDA for YUTREPIA. Accordingly, the FDA is not able to issue an action letter in time to meet the previously issued Prescription Drug User Fee Act goal date of January 24, 2024, and their review remains ongoing. The FDA did not request any additional clinical data to support the NDA and did not issue a new PDUFA goal date. Dr. Roger Jeffs, CEO, said: "We are in active communication with the FDA regarding the process we followed to amend our NDA to add PH-ILD to the labeled indication. Whether the NDA is amended or supplemented, we will continue to prepare for the final FDA approval of YUTREPIA to treat both PAH and PH-ILD patients following the expiration of regulatory exclusivity for Tyvaso on March 31, 2024. As communicated by the tentative approval to treat PAH, YUTREPIA has already met the regulatory standards for quality, safety and efficacy. We remain committed to addressing the unmet needs across all patients whose lives may be improved by the unique benefits of YUTREPIA."

05:53 EST Tesla falls 8% to $191.35 after Q4 report brings downgrade, target cuts

05:41 EST Velo3D secures $12M in new order bookings since mid-December - The company said, "Velo3D, Inc. announced four key strategic priorities for growth in 2024 and beyond. The company also shared progress it has made across these priorities. Enhance the quality of newly manufactured Sapphire printers: Due to the success of its operational initiatives and product improvements, the company has significantly reduced the installation time of Sapphire printers over the last year. Additionally, the company has increased headcount of its Customer Service and Quality teams by approximately 40% to provide on-site support in all major metropolitan areas. Ensure the success of customers in the field: Through reliability improvements, system uptime for key customers has increased over the previous quarter and the company has reduced the time it takes to resolve customer issues by more than 45% over the past 6 months. Velo3D's research and development priorities have been refocused on customer success and machine throughput, with innovations that the company expects will greatly increase customer available print time. Increase revenue visibly through bookings growth: The Velo3D Sales team has secured approximately $12 million in new order bookings since mid-December, including more than 50% of bookings tied to key strategic accounts, which the company believes demonstrates increased customer satisfaction and confidence in its technology. Improve margins and cash flow: The company remains on track to reduce its operational expenses by 40% by the end of the first quarter of 2024, with a commitment to become cash flow positive in the second half of the year."

05:24 EST Xiao-I, ABB enter partnership based on Hua Zang Universal Large Language Model - Xiao-I held the signing ceremony for a strategic cooperation framework agreement with ABB Group on November 23, 2023, in Shanghai. Du Yuqing, senior VP and Zhang Xudong, senior director, from Xiao-I, attended the signing ceremony. Xiao-I and ABB will leverage their platform resources and innovation capabilities to foster collaborative cooperation in fields such as smart parks, with the common goal of advancing long-term development through mutually beneficial partnerships. With a history of over 130 years and headquartered in Zurich, Switzerland, ABB established a manufacturing factory in Xiamen as early as 1992. ABB collaborates with globally oriented enterprises to create customized products. In the era of AI, the emergence of smart parks signifies a new trend in enterprise advancement. The combination of traditional industrial parks and modern information technology will create a more efficient and intelligent development environment for enterprises. Based on the Hua Zang Universal Large Language Model's core features of "controllable", "customizable" and "deliverable", this strategic collaboration between Xiao-I and ABB will promote cooperation in multiple fields, fostering the digitalization and intelligent development of industries.

05:11 EST UP Fintech announces upgrade of Type 1 license to include virtual asset dealing - UP Fintech announced that its Hong Kong subsidiary has officially upgraded its Type 1 license to include virtual asset dealing service, making it one of the first mainstream online brokerage firms in Hong Kong to receive approval for such a license upgrade. This successful upgrade opens the door for providing cryptocurrency trading services to Professional Investor clients in Hong Kong through its flagship platform, Tiger Trade. By integrating Tiger Brokers' technology-driven brokerage expertise, the company aims to offer Professional Investors in Hong Kong an unparalleled convenience of seamless trading of both traditional securities and cryptocurrencies on a unified platform. In the future, the company also plans to open virtual asset trading to retail investors, subject to authorities' approval. After this upgrade, eligible clients, including Hong Kong residents with over HKD 8M in investable assets or corporate with assets exceeding HKD 40M, can incorporate cryptocurrency trading into their portfolios alongside other asset classes available on our flagship platform Tiger Trade. In the future, residents of Hong Kong can conveniently trade virtual assets such as Bitcoin and Ethereum alongside stocks, options, futures, funds, and ETFs-all in one place. With centralized investment management, this enables local clients to measure their risk exposure across different asset classes.